Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telatinib + Keytruda in Advanced Stomach/GEJ Cancer and HCC
NCT04798781Phase 2Completed
- Start
- Jul 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telatinib in gastric cancer (GC), gastroesophageal junction cancer, hepatocellular carcinoma (HCC). Started Jul 2021; status: completed.
02
Drugs
telatinib
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04798781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798781.